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Point-of-care serological assays for delayed SARS-CoV-2 case 
identification among health-care workers in the UK: 
a prospective multicentre cohort study
Scott J C Pallett, Michael Rayment, Aatish Patel, Sophia A M Fitzgerald-Smith, Sarah J Denny, Esmita Charani, Annabelle L Mai, 
Kimberly C Gilmour, James Hatcher, Christopher Scott, Paul Randell, Nabeela Mughal, Rachael Jones, Luke S P Moore*, Gary W Davies*
Summary
Background Health-care workers constitute a high-risk population for acquisition of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection. Capacity for acute diagnosis via PCR testing was limited for 
individuals with mild to moderate SARS-CoV-2 infection in the early phase of the COVID-19 pandemic and a 
substantial proportion of health-care workers with suspected infection were not tested. We aimed to investigate the 
performance of point-of-care and laboratory serology assays and their utility in late case identification, and to 
estimate SARS-CoV-2 seroprevalence.
Methods We did a prospective multicentre cohort study between April 8 and June 12, 2020, in two phases. Symptomatic 
health-care workers with mild to moderate symptoms were eligible to participate 14 days after onset of COVID-19 
symptoms, as per the Public Health England (PHE) case definition. Health-care workers were recruited to the 
asymptomatic cohort if they had not developed PHE-defined COVID-19 symptoms since Dec 1, 2019. In phase 1, two 
point-of-care lateral flow serological assays, the Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK 
Bitotech, Poway, CA, USA) and the Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device (Zhuhai Encode 
Medical Engineering, Zhuhai, China), were evaluated for performance against a laboratory immunoassay (EDI Novel 
Coronavirus COVID-19 IgG ELISA kit [Epitope Diagnostics, San Diego, CA, USA]) in 300 samples from health-care 
workers and 100 pre-COVID-19 negative control samples. In phase 2 (n=6440), serosurveillance was done among 
1299 (93·4%) of 1391 health-care workers reporting symptoms, and in a subset of asymptomatic health-care workers 
(405 [8·0%] of 5049).
Findings There was variation in test performance between the lateral flow serological assays; however, the Encode assay 
displayed reasonable IgG sensitivity (127 of 136; 93·4% [95% CI 87·8–96·9]) and specificity (99 of 100; 99·0% 
[94·6–100·0]) among PCR-proven cases and good agreement (282 of 300; 94·0% [91·3–96·7]) with the laboratory 
immunoassay. By contrast, the Onsite assay had reduced sensitivity (120 of 136; 88·2% [95% CI 81·6–93·1]) and 
specificity (94 of 100; 94·0% [87·4–97·8]) and agreement (254 of 300; 84·7% [80·6–88·7]). Five (7%) of 70 PCR-positive 
cases were negative across all assays. Late changes in lateral flow serological assay bands were recorded in 74 (9·3%) of 
800 cassettes (35 [8·8%] of 400 Encode assays; 39 [9·8%] of 400 Onsite assays), but only seven (all Onsite assays) of these 
changes were concordant with the laboratory immunoassay. In phase 2, seroprevalence among the workforce was 
estimated to be 10·6% (95% CI 7·6–13·6) in asymptomatic health-care workers and 44·7% (42·0–47·4) in symptomatic 
health-care workers. Seroprevalence across the entire workforce was estimated at 18·0% (95% CI 17·0–18·9).
Interpretation Although a good positive predictive value was observed with both lateral flow serological assays and 
ELISA, this agreement only occurred if the pre-test probability was modified by a strict clinical case definition. Late 
development of lateral flow serological assay bands would preclude postal strategies and potentially home testing. 
Identification of false-negative results among health-care workers across all assays suggest caution in interpretation 
of IgG results at this stage; for now, testing is perhaps best delivered in a clinical setting, supported by government 
advice about physical distancing.
Funding None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) spread extensively following its identifi-
cation in December, 2019, becoming a global pandemic by 
March, 2020. More than 13 800 000 cases have been 
reported and 593 000 deaths attributed to COVID-19 
worldwide, as of July 18, 2020.1 Substantial public health 
isolation measures have been adopted in an attempt to 
slow the spread of infection. Case finding strategies have 
predominantly relied on PCR assays during the acute 
infection phase, through centralised specialist laboratories. 
In the UK, testing capacity in the early period of the 
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COVID-19 pandemic was mostly limited to patients who 
were admitted to hospital with COVID-19 symptoms, and 
only later extended to include symptomatic health-care 
workers. Health-care workers constitute a population that 
is at substantially greater risk of con tracting SARS-CoV-2 
infection due to the rate and nature of exposure associated 
with clinical care of positive cases. Personal protective 
equipment (PPE) and stringent infection prevention and 
control measures aim to mitigate this risk and minimise 
both nosocomial infection of health-care workers and 
onward trans mission.2 During the initial period, when the 
case rate was at its peak but PCR testing was not yet widely 
available, a large proportion of symptomatic health-care 
workers were not tested. Thus, SARS-CoV-2 prevalence 
among UK health-care workers remains largely unknown. 
Where the infection rate in asymptomatic health-care 
workers is similar to that seen in general community 
transmission,3 targeted testing of sympto matic individuals 
might be better placed to inform infection rates among 
health-care workers.
A variety of pathways to enhance case finding have 
been considered. These include point-of-care molecular 
platforms for acute phase testing, and laboratory 
ELISA or lateral flow serological assays for antibodies 
specific to SARS-CoV-2 for delayed case identification.4–6 
Although lateral flow serological assays potentially offer 
rapid results in either the point-of-care setting or home 
reading or postal testing, concern exists around test 
performance characteristics, particularly in the first 
2 weeks after onset of symptoms, as well as their poor 
positive predictive value when applied to a general 
population.6 By contrast, although laboratory-based 
ELISA kits might offer improved test performance 
characteristics, they have undergone only limited 
clinical evaluation.
We have previously evaluated the performance of 
lateral flow serological assays against PCR in moderate 
to severe SARS-CoV-2 infection.6 In the present study 
we aimed to explore the utility of these assays in a 
population of health-care workers with mild to moderate 
community-managed SARS-CoV-2 infection (all health-
care workers delivering direct clinical care to high-acuity 
SARS-CoV-2-positive patients). We compared two lateral 
flow serological assays against laboratory-based ELISA 
and PCR, where available, doing an interval analysis of 
test performance characteristics and their suitability for 
Research in context
Evidence before this study
The evidence for the performance and limitations of various 
serological assays for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is scarce. We searched PubMed for 
academic publications and online search engines for relevant 
grey literature on May 1, 2020, and repeated the search on 
May 26, 2020. A summary provided by Wu and McGoogan in 
February, 2020, of characteristics and important lessons from 
China, highlighted the considerable risk to health-care workers 
of the potential for nosocomial infection. Studies by Hunter 
and colleagues and Treiber and colleagues provide further 
insight, through PCR testing, into the burden of COVID-19 in 
health-care workers in the UK. The capacity to test health-care 
workers during the early phase of the COVID-19 pandemic in 
the UK was limited but can now be mitigated by delayed case 
identification through serology testing, providing insight into 
the overall burden of SARS-CoV-2 infection among health-care 
workers. To date, suitably sized studies have not yet been done 
in the UK. 
Added value of this study
This prospective, multicentre cohort study demonstrates the 
comparative utility of SARS-CoV-2 serology tests, looking at 
both lateral flow assays and ELISA approaches. Our study also 
provides one of the first large-scale insights into seroprevalence 
data in a cohort of health-care workers with high COVID-19 
exposure in the UK. Methodologically, demonstration of 
colorimetric band intensity on lateral flow assays and its 
correlation with optical density on ELISA provides a degree of 
confidence in the interpretation of high-intensity bands but 
reinforces the limitations of interpretation of lateral flow assays 
(and risks identification of false positives) when the bands 
appear weak. Additionally, our study is the first to demonstrate 
the substantial risks associated with delayed reading of lateral 
flow assays (in terms of both false positives and false negatives) 
and is informative when considering delayed reading 
(eg, postal testing) as part of a testing strategy if shared at this 
early stage in the planning process.
Implications of all the available evidence
Variation in performance characteristics between assays 
highlights the urgent need for individual evaluation of the large 
number of commercial SARS-CoV-2 serology tests that have 
become rapidly available. Practically, the observation of false-
negative serology results among health-care workers provides 
valuable information considering their messaging around 
interpretation of serology results at this early stage in the scale 
up of serological testing. False-negative results have a clear 
impact on the manner in which serological testing might be used 
to augment and support physical distancing policies, as well as 
implications for the development of large-scale testing 
pathways. Further research is required into the full scope of 
serological testing for SARS-CoV-2 infection and factors 
associated with failing to mount a detectable immune response 
to SARS-CoV-2 infection in otherwise healthy individuals. This 
study also demonstrates the potential limitations of single-
target immunoassays for SARS-CoV-2 and should help inform 
future research studies, where further evaluation is required not 
just of alternative assays but also through the comparison of the 
various epitope targets that are currently available.
Articles
www.thelancet.com/respiratory   Published online July 24, 2020    https://doi.org/10.1016/S2213-2600(20)30315-5 3
delayed case identification. Subsequent screening of the 
remaining symptomatic health-care workers was com-
pleted to assess seroprevalence.
Methods
Study setting and design
A prospective multicentre SARS-CoV-2 serological 
testing programme was implemented on April 8, 2020, 
and data were collected until June 12, 2020, across two 
hospitals in London, UK, comprising 6440 employees. 
Health-care workers were eligible for serological testing 
if they had delivered direct clinical care to SARS-CoV-2-
positive inpatients in cohort areas or isolation rooms 
involving aerosol-generating procedures; and had 
experienced mild to moderate symptoms matching the 
Public Health England (PHE) case definition7 for 
SARS-CoV-2 infection, including fever or cough, or both, 
with breathlessness or anosmia, or both, with onset at 
least 14 days before testing.
Specialist staff (redeployed from HIV and sexual 
health services) screened staff for clinical symptoms; 
collected demographic data (including age, sex, ethnicity, 
and job role); and carried out venepuncture for the 
serum sample facilitating inoculation of the point-of-
care lateral flow serological assay and matched laboratory 
ELISA.
The study was done in two phases. Phase 1 involved 
an evaluation of serology performance characteristics, 
comparing the matched lateral flow serological assays 
with ELISA. Phase 2 comprised an estimate of sero-
prevalence in symptomatic and asymptomatic health-care 
workers through further lateral flow serological assay 
testing. An interval analysis was done once testing had 
occurred for at least 90% of the reported number of 
symptomatic health-care workers to human resources 
during the study period (reached on June 12, 2020). 
Health-care workers were recruited to the asymptomatic 
cohort if they had satisfied inclusion criteria as above but 
had not experienced any PHE-defined COVID-19 symp-
toms since Dec 1, 2019. Recruitment was consecutive. 
Statistical analysis was done with IBM SPSS Statistics 
(version 26). A STARD (Standards for Reporting of 
Diagnostic Accuracy Studies) checklist is available in the 
appendix (pp 5–6).
Phase 1: serological testing
Lateral flow serological assay testing was done with the 
Onsite CTK Biotech COVID-19 split IgG/IgM Rapid 
Test (CTK Biotech, Poway, CA, USA) and the Encode 
SARS-CoV-2 split IgM/IgG One Step Rapid Test Device 
(Zhuhai Encode Medical Engineering, Zhuhai, China). 
Lateral flow serological assays were completed as per the 
manufacturers’ instruction leaflets. Lateral flow sero-
logical assays were read at 15 min by two clinical staff 
experienced in the use of point-of-care analysis 
(appendix p 4). Lateral flow serological assay readers, and 
subsequently ELISA staff, were masked with respect to 
any previous PCR results. A visual scoring system for 
evaluating immunochromatography rapid diagnostic kits 
has previously been described for chikungunya virus.8 
Based on this system, lateral flow serological assays were 
recorded as positive or negative with readings visually 
scored as absent (0), very weak positive (1), weak positive 
(2), medium positive (3) or strong positive (4), and 
compared with ELISA optical density readings. SDs of 
values in each visual group were compared with overall 
results. The mean ranks were compared for significance 
by use of the Kruskal-Wallis test. Dunn’s post-hoc tests 
were then done for pairwise comparisons and results 
reported as p values, with a significance threshold of 
p<0·050.
Comparator ELISA testing was done with the qualitative 
EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope 
Diagnostics, San Diego, CA, USA), targeting IgG anti-
bodies to the nucleocapsid protein of SARS-CoV-2. 
Post-marketing manufacturer information reported a 
sensitivity of 98·4% and specificity of 99·8%.9 ELISA was 
completed as per the manufacturer instruction leaflet and 
results were recorded as an optical density reading.9 
Where equivocal results were found, confirmation testing 
was done with the Abbott SARS-CoV-2 IgG (anti-
nucleocapsid) chemi luminescent microparticle immuno-
assay (Abbott Laboratories, Lake Bluff, IL, USA) on the 
ARCHITECT i1000SR immunoassay analyser and the 
final result included in the analysis.10
Phase 1: determining test performance characteristics
To derive a measure of sensitivity, the results of lateral 
flow serological assays and ELISA were compared in 
300  health-care workers who had previously received 
PCR testing (AusDiagnostics, Sydney, Australia) at initial 
presentation with COVID-19 symptoms. As per local 
hospital guidelines, PCR testing was done where possible 
between days 1 to 7 inclusive since onset of symptoms. A 
measure of specificity was derived through testing, with 
ELISA and lateral flow serological assays, of historical 
negative serum samples (50 samples from among patients 
with infectious or inflammatory presen tations from 
August, 2018, and 50 maternal antenatal screening 
samples from August, 2019). A further evalu ation was 
made on agree ment between lateral flow serological assay 
results and ELISA through interpretation of lateral flow 
serological assay visual scores in relation to ELISA optical 
density readings, particularly very weak and weak positive 
bands, to identify potential issues with variability in 
reading of lateral flow serological assays. Lateral flow 
serological assay cassettes were observed at 15 min post-
sampling, 2 h post-sampling, and 24 h post-sampling, and 
readings recorded. If a change was noted in the appearance 
of a band (negative to positive reading) or disappearance 
of a band (positive to negative reading) at 2 h or 24 h, a 
correlation was made against the ELISA result to establish 
the risk of late readings (eg, if postal return methods are 
used in conjunction with self-testing).
See Online for appendix
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Phase 2: determining SARS-CoV-2 seroprevalence in 
health-care workers
Phase 1 of the study analysed ELISA against both lateral 
flow serological assays. In phase 2, the remaining health-
care workers fulfilling the inclusion criteria were invited 
for serological testing with a lateral flow serological assay. 
To assess the significance of the sensitivity of the lateral 
flow serological assays (using an estimated sensitivity 
of 90%), we did a power calculation, setting α at 0·05 and 
β at 0·20.11 We estimated symptomatic infection to be 
90% among health-care workers. We calculated that the 
study would require 132 PCR-positive health-care 
workers in phase 2. In order to achieve this sample size, 
based on self-reporting of PCR-positive cases to human 
resources, we estimated that testing coverage in phase 2 
would need to capture at least 90% of all reported 
symptomatic health-care workers.
Additionally, following an update in government advice 
in mid-May, 2020, to offer testing to asymptomatic 
health-care workers,12 we tested a subset of asymptomatic 
health-care workers who were offered serology testing in 
order to more accurately estimate SARS-CoV-2 sero-
prevalence in the entire workforce.
Positive and negative predictive values based on test 
performance characteristics were then calculated if 
considered for use in three cohorts: in the UK general 
Figure 1: Results of health-care workers and negative controls tested with IgG ELISA and Encode and Onsite split IgM/IgG antibody lateral flow serological assays in London, UK, from 
April to June, 2020
Phase 1: comparison of matched samples tested with the Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK Biotech, Poway, CA, USA) and Encode SARS-CoV-2 split IgM/IgG One Step Rapid 
Test Device (Zhuhai Encode Medical Engineering, Zhuhai, China) LFAs and ELISA (EDI Novel Coronavirus COVID-19 IgG ELISA kit [Epitope Diagnostics, San Diego, CA, USA]). 100 historical serum 
samples were evaluated to assess specificity (tables 2, 3). Equivocal results were retested with the Abbott SARS-CoV-2 IgG (anti-nucleocapsid) chemi luminescent microparticle immuno assay (Abbott 
Laboratories, Lake Bluff, IL, USA). Phase 2: further analysis of LFA testing offered to all symptomatic health-care workers, including initial LFAs tested in phase 1 (n=300) and phase 2 (n=1299). Further 
analysis of asymptomatic health-care workers with LFA testing (n=405). LFA=lateral flow serological assay. PHE=Public Health England.
400 study
participants
300 samples from health-care
 workers (14 days since 
 onset of symptoms as per 
 PHE case definition)
1299 symptomatic
health-care workers
405 asymptomatic 
health-care workers
100 negative control samples
 50 maternal antenatal
 samples (2019)
 50 serum saves (2018)
6 of 100 ELISA equivocal
Retest: 6 of 6 negative
141 of 300 ELISA  
positive
95 of 100 ELISA negative
99 of 100 LFA negative with Encode 
94 of 100 LFA negative with Onsite
138 of 141 IgG positive with 
Encode 
123 of 141 IgG positive with 
Onsite 
1 of 141 IgM-only positive with 
Encode (2 of 141 negative with 
Encode)
6 of 141 IgM-only positive with 
Onsite (12 of 141 negative with 
Onsite)
159 of 300 ELISA 
negative
Phase 1
Phase 2
144 of 159 IgG negative
with Encode (7 of 159
IgM-only positive with 
Encode)
131 of 159 IgG negative 
with Onsite (5 of 159 
IgM-only positive with 
Onsite)
15 of 159 IgG positive with Encode
28 of 159 IgG positive with Onsite
581 of 1299 LFA IgG positive 34 of 1299 LFA IgM-only positive
684 of 1299 LFA negative
43 of 405 LFA IgG positive 11 of 405 LFA IgM positive
351 of 405 LFA negative
18 of 300 ELISA equivocal
Retest: 12 of 18 positive,
6 of 18 negative
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population (based on estimates of UK prevalence during 
our cohort’s period of majority reported symptom onset 
of 2·7%);13 in the asymptomatic health-care worker 
population if general screening was to be applied, with a 
derived prevalence from a subset of asymptomatic 
health-care workers; and in health-care workers reporting 
PHE-defined symptoms during the study period, with a 
derived prevalence from serological testing of symp-
tomatic health-care workers.
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
In phase 1 we compared matched two-way lateral flow 
serological assays against ELISA for 300 serum samples 
from health-care workers with an additional 100 historical 
pre-COVID-19-negative control samples (figure 1). The 
mean age of health-care workers in this cohort was 
39·1 years (range 22·7–71·0) and 218 (72·7%) of 
300 health-care workers were female. 70 (23·3%) of 
300 health-care workers had a suitably timed positive PCR 
result before serology testing (table 1). In phase 2, sero-
surveillance was done among 1299 (93·4%) of 1391 health-
care workers reporting symptoms and in 405 (8·0%) of 
5049 asymptomatic health-care workers. All health-care 
workers were tested more than 14 days after onset of 
symptoms. 592 (45·6%) of 1299 health-care workers were 
tested more than 21 days (range 14–54) after symptom 
onset. 24 (6·0%) of 400 samples (18 of 300 health-care 
workers, six of 100 negative controls) returned equivocal 
ELISA results. Upon confirmation testing with the Abbott 
SARS-CoV-2 IgG assay, 12 of 18 samples from health-care 
workers were positive and all six control group samples 
were negative. All 400 samples were included in the 
analysis. No lateral flow serological assay cassette failures 
were noted.
All 100 negative controls were included (mean age 
38·7 years [range 2·0–80·1]; 79 [79·0%] of 100 individuals 
in the control group were female). Relevant virology and 
serology data are presented in the appendix (p 3).
Samples from all 300 health-care workers were run 
against both lateral flow serological assays and laboratory 
immunoassays. 141 (47%) of 300 samples had a positive 
IgG ELISA result; 138 (98%) of 141 were positive on the 
Encode lateral flow serological assay and 123 (87%) were 
positive on the Onsite lateral flow serological assay 
(figure 1). IgM-only positive cassettes were reported on 
the Encode lateral flow serological assay (eight [2·7%] of 
300) and Onsite lateral flow serological assay (11 [3·7%] 
of 300). Of the 300 health-care workers evaluated, 
159 (53%) had a negative IgG ELISA result; 144 (91%) of 
159 were IgG negative on the Encode lateral flow 
serological assay and 131 (82%) of 159 were negative on 
the Onsite lateral flow serological assay (figure 1). 
Agreement between results for ELISA with Encode 
lateral flow serological assays was seen for 282 of 
300 samples (94·0% [95% CI 91·3–96·7]), for ELISA with 
Onsite lateral flow serological assays agreement was seen 
for 254 of 300 samples (84·7% [80·6–88·7]) and for 
Encode with Onsite lateral flow serological assays 
agreement was seen for 262 of 300 samples (87·3% 
[83·6–91·1]; tables 2, 3).
70 (23·3%) of 300 health-care workers had positive 
SARS-CoV-2 PCR results from the time of initial 
symptom onset. 60 (85·7% [95% CI 75·3–92·9]) of these 
70 samples were positive on laboratory ELISA (table 1). 
65 (92·9% [95% CI 84·1–97·6]) of 70 samples were 
positive on the Encode lateral flow serological assay, 
whereas 63 (90·0% [80·5–95·9]) of 70 were positive with 
the Onsite lateral flow serological assay (table 1). All PCR-
positive cases reported as IgG positive on ELISA were 
also positive on the Encode lateral flow serological assay. 
Five (7%) of 70 samples that were negative on laboratory 
ELISA were also negative on both lateral flow serological 
assays. 29 health-care workers had a negative PCR 
recorded. Of these, 27 (93·1%) of 29 were negative on 
Phase 1 Phase 2
PCR positive (n=70) Sensitivity PCR positive (n=136) Sensitivity
ELISA positive 60 85·7% (95% CI 75·3–92·9) NA NA
ELISA negative 10 ·· NA ··
Encode LFA positive 65 92·9% (95 CI 84·1–97·6) 127 93·4% (95% CI 87·8–96·9)
Encode LFA negative 5 ·· 9 ··
Onsite LFA positive 63 90·0% (95% CI 80·5–95·9) 120 88·2% (95% CI 81·6–93·1)
Onsite LFA negative 7 ·· 16 ··
ELISA=EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, San Diego, CA, USA). NA=not available. Encode=Encode SARS-CoV-2 split IgM/IgG One Step 
Rapid Test Device (Zhuhai Encode Medical Engineering, Zhuhai, China). LFA=lateral flow serological assay. Onsite=Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK 
Bitotech, Poway, CA, USA). Where equivocal results were found on ELISA sampling, testing was repeated with the Abbott SARS-CoV-2 IgG (anti-nucleocapsid) chemi-
luminescent microparticle immuno assay (Abbott Laboratories, Lake Bluff, IL, USA). Phase 1: total PCR-positive matched health-care workers in phase 1 (70 of 300). Phase 2: 
matched LFA results in 136 PCR-positive health-care workers (AusDiagnostics, Sydney, Australia). 
Table 1: Sensitivity of ELISA, Encode LFA, and Onsite LFA in PCR-positive health-care workers in London, UK, in April–June, 2020
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ELISA and the Encode lateral flow serological assay. 
26 (89·7%) of 29 were negative on the Onsite lateral flow 
serological assay.
95 of 100 ELISA-run samples were IgG negative 
(specificity 95·0% [95% CI 88·7–98·4]), 99 of 100 Encode 
lateral flow serological assays were IgG negative (speci-
ficity 99·0% [94·6–100·0]), and 94 of 100 Onsite lateral 
flow serological assays were IgG negative (specificity 
94·0% [87·4–97·8]; table 2).
Where visual scores of lateral flow serological assays 
were recorded at 15 min for band visibility, these were 
compared to laboratory ELISA optical density readings 
(figure 2; appendix pp 1–2). Where the Encode assay was 
reported to have reactive bands (153 [51·0%] of 300), the 
appearance of bands was recorded as very weak (16 [10·5%] 
of 153), weak (51 [33·3%] of 153), medium (44 [28·8%] of 
153), or strong (42 [27·5%] of 153). Three (2·0%) of 
147 negative Encode assays were IgG positive on ELISA, 
and 15 (9·8%) of 153 positive Encode assays were negative 
on ELISA (seven very weak, six weak, and two medium; 
appendix p 1). Where the Onsite assay was reported to have 
reactive bands (151 [50·3%] of 300), the appearance of 
bands was recorded as very weak (30 [19·9%] of 151), weak 
(32 [21·2%] of 151), medium (41 [27·2%] of 151), or strong 
(48 [31·8%] of 151). 18 (12·1%) of 149 negative Onsite 
assays were positive on ELISA testing, and 28 (18·5%) of 
151 positive Onsite assays were negative on ELISA testing 
(13 very weak, eight weak, six medium, one strong; 
appendix p 2). Kruskal-Wallis testing of visual scores for 
Encode and Onsite lateral flow serological assays against 
optical density showed a significant difference between 
groups (p<0·0001). SDs were calculated for each visual 
score and Dunn’s pairwise tests were done between paired 
groups (figure 2).
All 800 lateral flow serological assay cassettes were read 
at 15 min, 2 h, and 24 h after sampling. At 2 h no change 
was noted from the initial readings. At 24 h a change was 
noted in 35 (8·8%) of 400 Encode lateral flow serological 
assay tests. 29 of 35 tests changed from negative to 
positive, and six of 35 changed from positive to negative. 
ELISA results were concordant with initial Encode lateral 
flow serological assay readings at 15 min. 39 (9·8%) of 
400 Onsite lateral flow serological assays also demon-
strated a change in readings at 24 h, with 15 of 39 cassettes 
changing from negative to positive (ELISA confirmed 
seven as positive and eight as negative) and 24 of 
39 becoming unreadable.
In phase 2, 1299 health-care workers working in high-
acuity areas were tested (including phase 1 participants) 
with a lateral flow serological assay (mean age 38·2 years 
[range 20·5–71·7]; 931 [71·7%] female). 581 (44·7%) of 
1299 participants had a positive IgG band, and 
684 (52·7%) were negative. 34 (2·6%) of 1299 health-care 
workers had an IgM-only band (figure 1). 1391 of 
6440 health-care workers reported PHE-defined 
symptoms up until the date of analysis. Where IgG 
seroprevalence among symptomatic health-care workers 
was estimated at 44·7% (95% CI 42·0–47·4), this 
corresponded to 622 of 1391 individuals. Of the 
1299 (93·4%) of 1391 health-care workers tested, 136 had 
a positive PCR result (table 1).
Of the 1299 symptomatic health-care workers, 
842 (64·8%) reported fever, 1043 reported cough (80·3%) 
and 298 (22·9%) reported anosmia. χ² testing for 
independent association of symptoms with seropositivity 
was significant for fever (χ² 9·01, p=0·0027) and anosmia 
(χ² 43·0, p<0·0001). A significant association was not 
found for cough (χ² 1·92, p=0·17).
405 asymptomatic health-care workers were tested 
(mean age 42·4 years [range 20·3–72·1]; 298 [73·6%] 
female). 43 (10·6%) of 405 asymptomatic health-care 
workers had a positive IgG band. 5049 health-care 
IgG ELISA 
positive
IgG ELISA 
negative*
Historic 
negative serum 
samples (n=100)
Agreement with ELISA 
IgG 
IgG specificity IgG plus IgM specificity
Encode LFA positive 138 15 1 ·· ·· ··
Encode LFA negative 3 144 99 94·0% (95% CI 91·3–96·7) 99·0% (95% CI 94·6–100·0) 98·0% (95% CI 93·0–99·8)
Onsite LFA positive 123 28 6 ·· ·· ··
Onsite LFA negative 18 131 94 84·7% (95% CI 80·6–88·7) 94·0% (95% CI 87·4–97·8) 94·0% (95% CI 87·4–97·8)
Encode=Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device (Zhuhai Encode Medical Engineering, Zhuhai, China). LFA=lateral flow serological assay. Onsite=Onsite 
CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK Bitotech, Poway, CA, USA). ELISA=EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, San Diego, CA, 
USA). *ELISA testing of historic negative samples showed 95 of 100 as negative: specificity 95·0% (95% CI 88·7–98·4).
Table 2: Agreement for IgG detection between Encode LFA and Onsite LFA and ELISA matched samples
Encode LFA 
positive
Encode LFA 
negative
Onsite LFA positive 137 24
Onsite LFA negative 14 125
Encode LFA and Onsite LFA 
agreement
87·3% (95% CI 
83·6–91·1)
87·3% (95% CI 
83·6–91·1)
LFA=lateral flow serological assay. Encode=Encode SARS-CoV-2 IgM/IgG One Step 
Rapid Test Devices (Zhuhai Encode Medical Engineering, Zhuhai, China). 
Onsite=Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK Biotech, 
Poway, CA, USA). Where equivocal results were found on ELISA (n=24), testing was 
repeated with the Abbott SARS-CoV-2 IgG (anti-nucleocapsid) chemi luminescent 
microparticle immuno assay(Abbott Laboratories, Lake Bluff, IL, USA). Specificity 
data are derived from testing of historical negative serum samples (n=100).
Table 3: Agreement between the Encode and Onsite LFAs
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workers had not experienced symptoms throughout the 
study period. IgG seroprevalence among sympto matic 
health-care workers was estimated therefore at 10·6% 
(95% CI 7·6–13·6), corresponding to 535 indi viduals. 
Estimated IgG seropositivity for the workforce was 
calculated through the combination of estimates for 
symptomatic health-care workers (622 [44·7%] of 1391) 
and asymptomatic health-care workers (535 [10·6%] 
of 5049). This would correspond to an estimated sero-
prevalence across the entire workforce of 18·0% (95% CI 
17·0–18·9).
Seroprevalence was considered in three separate cohorts 
as described. In the UK general population (2·7%),13 for 
Onsite the positive predictive value was 29·0% (95% CI 
15·8–47·1) and negative predictive value was 99·7% 
(99·5–99·8); and for Encode the positive predictive value 
was 72·2% (26·9–94·8) and negative predictive value 
99·8% (99·7–99·9). In the asymptomatic health-care 
worker cohort (10·6%), for Onsite the positive predictive 
value was 63·6% (95% CI 44·5–79·2) and negative 
predictive value was 98·5% (97·7–99·1); and for Encode 
the positive predictive value was 91·7% (61·2–98·7) and 
negative predictive value was 99·2% (98·5–99·6). In 
health-care workers reporting symptoms (44·7% of 
symptomatic health-care workers), for Onsite the positive 
predictive value was 92·2% (95% CI 84·5–96·3) and 
negative predictive value was 90·8% (86·2–94·0); and 
for Encode the positive predictive value was 98·7% 
(91·5–99·8) and negative predictive value was 94·9% 
(90·8–97·2).
Discussion
In this study we report good positive and negative 
predictive values for delayed serological testing in a 
carefully selected population with suspected SARS-CoV-2 
infection. These findings have the potential to support 
case identification strategies, depending on the device 
used. Testing could be particularly useful in improving 
our understanding of the true prevalence of community 
managed, mild to moderate infection among high-risk 
health-care workers while informing the analysis of 
infection prevention and control strategies for any future 
waves of the ongoing COVID-19 pandemic.
Testing in this high-exposure cohort based in London, 
UK, has identified several key lessons that could 
substantially affect future plans for wider serological 
testing among health-care workers.
Although a wide range of rapid diagnostic point-of-care 
serological assays have emerged in a short period of time, 
individual assay analysis has been challenging in 
individuals with mild to moderate infection as numbers 
of so-called true-positive PCR-tested individuals available 
for comparison are limited. Concerns about variability in 
sensitivity between lateral flow serological assays are 
borne out in our data, when these assays were compared 
against laboratory ELISAs. We demonstrate good 
agreement for detection of IgG with the Encode lateral 
flow serological assay when our pre-test criteria are 
applied (94·0%); however, there was reduced agreement 
with the Onsite lateral flow serological assay (84·7%). 
This result would therefore limit the utility of the Onsite 
assay even within the high-risk health-care worker 
population, where a much higher pre-test probability 
exists than in the general population. Among the PCR-
positive subgroup, results were concordant between 
individual assays, with the Encode lateral flow serological 
assay identifying 100%, and the Onsite 97%, of health-
care workers who were also positive on ELISA. The failure 
of all three assays to identify PCR-positive health-care 
workers with PHE-defined symptoms highlights the 
limitations of relying on any single diagnostic platform, 
or perhaps identifies a cohort of individuals who did not 
mount a timely serological response.
Where reduced sensitivity among serological assays in 
the early infection period has been previously described,6,14 
Figure 2: Distribution of visual scores for Encode (A) and Onsite (B) LFAs against optical density readings of 
ELISA-matched samples
Readings of the Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK Biotech, Poway, CA, USA) and the 
Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device (Zhuhai Encode Medical Engineering, Zhuhai, China) 
LFAs at 15 min plotted against ELISA (EDI Novel Coronavirus COVID-19 IgG ELISA kit [Epitope Diagnostics, 
San Diego, CA, USA]) optical density for all health-care worker matched samples (n=300). Scoring correlates to a 
negative (0), very weak positive (1), weak positive (2), medium positive (3), and strong positive (4) reading. 
Reference photographs selected from mean optical density value cassette for each score. SDs of Encode lateral flow 
serological assay values: negative (0·09), very weak (0·21), weak (0·26), medium (0·21), and strong (0·20) visual 
scores. Dunn’s pairwise tests showed no significant difference between visual scores, comparing very weak to 
medium (p=0·35), medium to strong (p=0·064), very weak to weak (p=1·00), and weak to medium (p=1·00) visual 
scores. All other pairwise comparisons had a significant relationship with optical density (p<0·0001). SDs of Onsite 
lateral flow serological assay values: negative (0·17), very weak (0·21), weak (0·23), medium (0·29), and 
strong (0·30) visual scores. Dunn’s pairwise tests showed no significant difference between visual scores comparing 
very weak to weak (p=1·00), weak to medium (p=0·062), and medium to strong (p=1·00) visual scores. All other 
pairwise comparisons had a significant relationship with optical density (p<0·0043).
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it is clear that any use of such assays in supporting early 
return-to-work policies could carry considerable risk. 
Such policies or recommendations should therefore be 
actively discouraged. Additionally, the proportion of 
individuals who are seronegative on both ELISA and 
lateral flow serological assays, despite being PCR-
positive, is of concern. Any use of serological testing 
should be accompanied with a reinforcement of PPE 
and infection, prevention and control advice, regardless 
of result, and therefore testing should be undertaken 
face to face in a clinical setting. Immunity inferred by 
the presence of antibodies is yet to be determined and 
clinical counselling of result interpretation at this stage 
as purely case identification is an important part of the 
testing process, preventing misunderstanding and incor-
rect behaviour modification (eg, relaxing physical 
distancing rules or reducing PPE). This assessment 
could be done at established UK National Health Service 
(NHS) facilities, as we have done here, or potentially 
done via mobile health units as demonstrated by early 
identification of HIV infection through point-of-care 
CD4 testing in South Africa.15
We found visual scoring of immunochromatography 
lateral flow serological assay bands to correlate with ELISA 
optical density. More prominent bands were seen in 
positive cases and the weakest bands were seen in those 
initially reported as equivocal. We did, however, find 
laboratory ELISA-negative samples with very weak lateral 
flow serological assay bands, casting doubt on the ability to 
interpret these results. The risk of reporting false positives 
is likely to be increased further by non-expert reading, 
such as with home testing seroprevalence studies. Where 
bands have a strong or medium immuno chromatography 
reading, however, ELISA was positive in almost all 
(84 [98%] of 86) cases for the Encode lateral flow serological 
assay, reflecting greater reliability. In com parison, seven of 
89 Onsite cassettes with medium to strong bands or strong 
bands were ELISA negative. Across both lateral flow 
serological assays, the finding of IgM-only bands might 
represent greater capability among the lateral flow 
serological assays to identify positive cases, or false-positive 
or cross-reactive IgM results. Among the historical 
negative samples, reactivation of Epstein-Barr virus might 
have accounted for a false-positive result. Although 
manufacturers have reported no observed cross-reactivity 
with seasonal coronaviruses, the sample sizes in the 
present study were not large enough and further evaluation 
is required in a larger cohort of health-care workers. An 
apparent failure to seroconvert to IgG among those with 
confirmed SARS-CoV-2 infection has been documented in 
one study and this effect might account for some of the 
IgM-only cases.16 Although we observed IgG-positive 
results in PCR-positive individuals as late as 2 months 
after symptom onset, the limited PCR positive rate among 
health-care workers makes analysis of test performance as 
a function of time difficult to assess in this study. Further 
analyses with alternative laboratory ELISA platforms, 
including those with IgM targets as well as IgG spike-
protein receptor-binding-domain targets (in addition to the 
nucleocapsid protein targets), are urgently required to 
determine the reasons for these discordant findings. 
Longitudinal serial testing will also be informative.
When considering the utility of lateral flow serological 
assays, one of the key benefits is the availability of real-
time results at the point of testing. Where we investigated 
delayed reading of lateral flow serological assay cassettes, 
a considerable number changed at 24 h, becoming either 
entirely unreadable or leading to the reporting of a 
different result. This effect has previously been reported 
with a high incidence of true non-reactive results 
changing to weak positive when undergoing delayed 
reading of rapid antibody tests for HIV.17 We therefore 
strongly advise against any use of lateral flow serological 
assays in home testing programmes that involve non-
expert reading of cassettes or return postage of samples 
for evaluation at extended time intervals.
Early work in PCR testing of health-care workers in 
the UK, through testing of symptomatic individuals but 
also through serial screening of asymptomatic indi-
viduals, suggests that infection rates in this cohort might 
reflect wider community transmission rather than 
primarily nosocomial infection.3,18 This observation is in 
keeping with first reports of large-scale testing of health-
care workers in China.19 Where PCR testing is not as 
widely available, serological testing offers an additional 
avenue for estimating infection rate among health-care 
workers. Where fewer than half of those working in the 
highest risk areas and presenting with PHE-defined 
symptoms had reactive results, estimation of total rates 
was similar to previously reported rates. However, we 
found some discordance in our asymptomatic cohort 
when compared to previously reported data. Serological 
screening done among health-care workers in Essen, 
Germany, found a seropositive rate of 1·6%, of which the 
majority of individuals did not report PHE-defined 
symptoms;20 yet in our study we reported a seroprevalence 
of 10·6%. Recent data from a study in Oxford, UK, 
however are supportive of our findings, where 
1016 (10·7%) of 9456 IgG-positive results were reported 
in a large asymptomatic health-care worker cohort.21 
Although all three studies were done during the same 
time period, the incidence rate and population density 
in the UK were considerably higher and such marked 
variation in seroconversion reflects the impact of 
geographical variation in exposure intensity and rein-
forces the need for granular serological data. In stark 
contrast to seroprevalence among individuals with PHE-
defined symptoms (44·7%), the findings from our 
asymptomatic cohort are perhaps more in keeping with 
the observed peak among the general population in 
London (7·1%),3 with a slight increase reflecting the 
increased exposure faced by health-care workers. There 
is growing evidence, however, that those with mild 
disease are less likely to produce a detectable antibody 
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response than those with more severe disease, and 
specifically those with lower respiratory tract 
involvement.22 A relative difference in exposure might 
also partly explain the observed variability in 
seroprevalence, with minimal doses of virus perhaps 
insufficient to induce an adaptive immune response, 
but instead dealt with by the innate immune system.23 In 
this context, until the differential antibody response 
and its neutralising capacity in SARS-CoV-2 are better 
understood, generalised testing of asymptomatic health-
care workers, where positive predictive value is sub-
stantially reduced, should be done only with considerable 
caution alongside detailed advice about the current 
limitations for interpretation. When pre-test criteria are 
applied (14 days after onset of PHE-defined symptoms), 
the positive predictive value is substantially increased. 
Further investigations among this cohort with anti-
receptor binding domain assays might provide additional 
information to the anti-nucleocapsid assay used here, 
where reduced sensitivity is a clear issue.
Although PCR is recognised as the gold standard in the 
diagnosis of acute SARS-CoV-2 infection, our study was 
limited to a subgroup analysis of PCR-positive health-care 
workers because of the reduced availability of PCR testing 
during the early phase of the pandemic. As PCR testing 
capacity was increased, we conversely noted a substantial 
decline in health-care workers presenting with acute 
phase symptoms. Where PCR data were available, reduced 
sensitivity for all three assays was observed compared to 
information provided by the manufacturer. This finding 
might reflect limitations in the use of these assays within 
individuals with mild to moderate infection, with many 
assay development characteristics reported in testing of 
inpatients with severe disease, and supports the require-
ment of individual assay evaluation within intended 
populations before widespread use. That our data 
demonstrate general agreement between lateral flow 
serological assays and PCR, however, is encouraging, but 
the reduced agreement among lateral flow serological 
assays in general is concerning. This potential discrepancy 
could be explained by the utilisation of separate assay 
targets (nucleocapsid or spike protein) in lateral flow 
serological assays. We were unable to discern further 
target information from both manufacturers. Where clear 
information remains unavailable for assay targets, as with 
many currently available commercial lateral flow sero-
logical assays, greater understanding of any neutralising 
effect of different antibodies will be even more important. 
Although our study was done at multiple sites, its capacity 
to reflect esti mated prevalence in secondary care facilities 
in London alone and elsewhere was probably limited; 
appropriately powered studies are now required in 
locations with a lower estimated prevalence to understand 
the likely prevalence among health-care workers at a 
national level. This study is further limited by the use of 
an IgG-target laboratory ELISA to the nucleocapsid 
protein only. Additional analysis with a laboratory ELISA 
capable of detecting the spike protein, and in particular 
the receptor binding domain, would allow for further 
evaluation of the reliability of the observed results with 
lateral flow serological assays.
In conclusion, serological testing, whether with 
laboratory-based ELISA platforms or lateral flow 
serological assays designed for use at the point of care, 
offer the potential for late case identification among 
health-care workers with mild to moderate SARS-CoV-2 
infection. We found variability in the performance of 
different lateral flow serological assays when compared 
against an IgG-target laboratory ELISA. Building on 
our previously reported work of moderate to severe 
SARS-CoV-2 infection among inpatients with PCR-
confirmed SARS-CoV-2 infection,6 we found suitable 
performance characteristics from the Encode lateral flow 
serological assay device (and slightly less so with Onsite) 
but only if utilised in patients with PHE-defined symp-
toms at least 14 days following symptom onset. Although 
lateral flow serological assays might provide a clear 
mechanism to identify those health-care workers who 
have contracted SARS-CoV-2 infection, it is crucial to 
note that cassettes provide incorrect results if delayed 
reading is done and this must be a key consideration for 
any future plans for large-scale testing with lateral flow 
serological assays.
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